Financials Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2023-12-01 pm EST Intraday chart for Iqvia Holdings Inc. 5-day change 1st Jan Change
216.91 USD +1.31% +2.31% +5.87%

Valuation

Fiscal Period : December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 23 239 29 981 34 352 53 900 38 056 39 586 - -
Enterprise Value (EV) 1 33 355 40 789 44 983 64 659 49 587 51 417 50 665 50 036
P/E ratio 93,7x 161x 125x 57,0x 35,8x 33,3x 29,6x 24,0x
Yield - - - - - - - -
Capitalization / Revenue 2,23x 2,70x 3,02x 3,88x 2,64x 2,66x 2,54x 2,36x
EV / Revenue 3,20x 3,68x 3,96x 4,66x 3,44x 3,45x 3,25x 2,98x
EV / EBITDA 15,0x 17,0x 18,9x 21,4x 14,8x 14,4x 13,3x 12,1x
EV / FCF 42,0x 48,8x 33,5x 28,1x 31,3x 32,3x 27,3x 23,9x
FCF Yield 2,38% 2,05% 2,99% 3,56% 3,20% 3,10% 3,66% 4,19%
Price to Book 3,50x 4,95x 5,71x 9,11x 6,60x 6,47x 5,55x 4,92x
Nbr of stocks (in thousands) 200 046 194 038 191 726 191 040 185 740 182 500 - -
Reference price 2 116 155 179 282 205 217 217 217
Announcement Date 02/14/19 02/12/20 02/10/21 02/15/22 02/10/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period : December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 10 412 11 088 11 359 13 874 14 410 14 902 15 603 16 789
EBITDA 1 2 224 2 400 2 384 3 022 3 346 3 565 3 802 4 134
EBIT 1 1 946 2 112 2 030 2 591 2 779 3 027 3 238 3 542
Operating Margin 18,7% 19,0% 17,9% 18,7% 19,3% 20,3% 20,8% 21,1%
Earnings before Tax (EBT) 1 328 352 373 1 128 1 363 1 519 1 705 2 045
Net income 1 259 191 279 966 1 091 1 225 1 361 1 637
Net margin 2,49% 1,72% 2,46% 6,96% 7,57% 8,22% 8,72% 9,75%
EPS 2 1,24 0,96 1,43 4,95 5,72 6,52 7,33 9,02
Free Cash Flow 1 795 835 1 343 2 302 1 586 1 594 1 856 2 095
FCF margin 7,64% 7,53% 11,8% 16,6% 11,0% 10,7% 11,9% 12,5%
FCF Conversion (EBITDA) 35,7% 34,8% 56,3% 76,2% 47,4% 44,7% 48,8% 50,7%
FCF Conversion (Net income) 307% 437% 481% 238% 145% 130% 136% 128%
Dividend per Share 2 - - - - - - - -
Announcement Date 14/02/19 12/02/20 10/02/21 15/02/22 10/02/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period : December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 3 438 3 391 3 636 3 568 3 541 3 562 3 739 3 652 3 728 3 736 3 785 3 786 3 871 3 932 4 020
EBITDA 1 722 728 828 812 800 814 920 851 864 888 961 893 929 956 1 029
EBIT 1 618 623 704 691 682 694 712 721 737 747 821 757 789 812 879
Operating Margin 18,0% 18,4% 19,4% 19,4% 19,3% 19,5% 19,0% 19,7% 19,8% 20,0% 21,7% 20,0% 20,4% 20,7% 21,9%
Earnings before Tax (EBT) 1 222 273 376 400 328 360 275 362 375 349 432 363 415 411 489
Net income 1 175 261 318 325 256 283 227 289 297 303 331 284 318 330 390
Net margin 5,09% 7,70% 8,75% 9,11% 7,23% 7,94% 6,07% 7,91% 7,97% 8,11% 8,75% 7,50% 8,22% 8,40% 9,69%
EPS 2 0,90 1,34 1,63 1,68 1,34 1,49 1,20 1,53 1,59 1,63 1,75 1,54 1,74 1,81 2,14
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 07/27/21 10/21/21 02/15/22 04/27/22 07/21/22 10/26/22 02/10/23 04/27/23 08/01/23 11/01/23 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period : December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 10 116 10 808 10 631 10 759 11 531 11 831 11 079 10 450
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 4,55x 4,50x 4,46x 3,56x 3,45x 3,32x 2,91x 2,53x
Free Cash Flow 1 795 835 1 343 2 302 1 586 1 594 1 856 2 095
ROE (net income / shareholders' equity) 15,7% 20,1% 20,9% 29,2% 32,8% 31,9% 31,0% 32,4%
Shareholders' equity 1 1 648 952 1 337 3 305 3 325 3 843 4 388 5 051
ROA (Net income/ Total Assets) 5,09% 5,57% 1,17% 7,15% 7,74% 6,04% 6,48% 7,36%
Assets 1 5 087 3 428 23 907 13 517 14 088 20 285 20 999 22 226
Book Value Per Share 2 33,2 31,2 31,4 31,0 31,0 33,5 39,1 44,1
Cash Flow per Share 2 6,02 7,10 10,0 15,1 11,9 12,7 14,6 16,2
Capex 1 459 582 616 640 674 642 662 711
Capex / Sales 4,41% 5,25% 5,42% 4,61% 4,68% 4,31% 4,25% 4,23%
Announcement Date 02/14/19 02/12/20 02/10/21 02/15/22 02/10/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
216.91USD
Average target price
229.52USD
Spread / Average Target
+5.81%
Consensus
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer